The brugada syndrome

被引：33
作者：
Brugada P. [1 ]
Brugada R. [2 ]
Brugada J. [3 ]
机构：
[1] Cardiovascular Center, OLV Hospital, 9300 Aalst
[2] Baylor College of Medicine, Houston, TX
[3] Arrhythmia Unit, Hospital Clinic, University of Barcelona
来源：
Current Cardiology Reports | 2000年 / 2卷 / 6期
关键词：
Sudden Death; Sudden Cardiac Death; Antiarrhythmic Drug; Flecainide; Brugada Syndrome;
D O I：
10.1007/s11886-000-0035-0
中图分类号：
学科分类号：
摘要：
The Brugada syndrome is a hereditary disease causing sudden cardiac death in apparently healthy individuals with a structurally normal heart. The disease is caused by mutations in the cardiac sodium channel gene SCN5A. Patients with this disease have a peculiar electrocardiogram with elevation of the ST segment in leads V1 to V3, an electrocardiogram that every doctor should recognize. There exist variants of the electrocardiogram with minimal ST segment elevation and even concealed forms that can only be unmasked by the administration of class I antiarrhythmic drugs. When left untreated or when treated with all known antiarrhythmic drugs, patients with Brugada syndrome have a high mortality (approximately 10% per year). The only effective treatment to prevent sudden death is the implantable defibrillator. Copyright © 2000 by Current Science Inc.
引用
收藏
页码：507 / 514
页数：7
相关论文
共 83 条
[81]  
Benhorin J., Taub R., Goldmit M., Et al., Effects of flecainide in patients with new SCN5A mutation. Mutation-specific therapy for long QT syndrome?, Circulation, 101, pp. 1698-1706, (2000)
[82]  
Brugada P., Brugada R., Brugada J., Sudden death in patients and relatives with the syndrome of right bundle branch block, ST segment elevation in the precordial leads V1 to V3 and sudden death, Eur Heart J, 21, pp. 321-326, (2000)
[83]  
Holtzman N.A., Marteau T.M., Will genetics revolutionize medicine ?, N Engl J Med, 343, pp. 141-144, (2000)
123456789